<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151343</url>
  </required_header>
  <id_info>
    <org_study_id>2016-775</org_study_id>
    <secondary_id>2016-003743-10</secondary_id>
    <nct_id>NCT03151343</nct_id>
  </id_info>
  <brief_title>SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk</brief_title>
  <acronym>SIMPLE</acronym>
  <official_title>Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caroline M Kistorp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with type 2 diabetes (T2 DM) have a markedly increased risk of heart disease and it
      is estimated that, in the danish population, up 80% percent of patients with type 2 diabetes
      die from heart disease.

      The sodium glucose cotransport-2 (SGLT-2) inhibitors were developed as an anti-diabetic
      therapy reducing blood glucose and weight by decreasing glucose reabsorption in the kidneys,
      leading to glucose excretion via the urine. However, in 2015 the EMPA-REG study showed that
      treatment with the SGLT-2 inhibitor empagliflozin significantly reduced the cardiovascular
      mortality and risk of admission under the diagnosis of heart failure in a population of
      patients with type 2 diabetes in addition to other risk factors for heart disease. The
      mechanism behind this surprising result is unknown and warrants further study.

      The primary hypothesis of the present study is that treatment with empagliflozin improves the
      function and blood supply of the heart muscle cells in patients with type 2 diabetes and high
      risk of heart disease. The investigators will test this hypothesis by enrolling 92
      participants with type 2 diabetes and other risk factors for heart disease, and treating them
      with either empagliflozin or a placebo. During the study period the investigators will
      monitor the effects of the treatment with various techniques such as heart scans using CT and
      ultrasound, measurements of the fluid pressures in the heart chambers, body composition
      measurements and a variety of relevant blood test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be treated with either empagliflozin or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rb-82 PET</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in myocardial flow reserve (MFR) by Rb-82 PET. Measured as change in global perfusion from rest to adenosine-induced stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive hemodynamics</measure>
    <time_frame>13 weeks</time_frame>
    <description>Substudy, performed on 38 participants from the main group. Using right heart catheterisation to measure pulmonary capillary weight pressure (PCWP) at 25 watts (supine bicycle ergometer)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in global left ventricular function assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in renal function assessed by Cr-51 EDTA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>U-alb/crea</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change urinary albumin/creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour BP</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in 24 hour BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave analysis</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in pulse wave analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>13 weeks</time_frame>
    <description>Changes in insulin resistance by Matsuda index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>13 weeks</time_frame>
    <description>Changes in insulin resistance by HOMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in NT-proBNP, MR-proANP, MR-proADM, GAL-3, hsTNT, GDF-15, PIGF, sFlt-1, FFA, ADPN, leptin, TNF-Î±, IL-6, MCP-1, MAC-1, COLL-A1, FGF-21, beta-hydroxybutyrate, AGEs CML, sRAGE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEXA</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in body composition by DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive hemodynamics - continued</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in CO at rest, 25 watts and peak exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive hemodynamics - continued</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in CVP at rest, 25 watts and peak exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive hemodynamics - continued</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in PCWP at rest, 25 watts and peak exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive hemodynamics - continued</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in PAP at rest, 25 watts and peak exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive hemodynamics - continued</measure>
    <time_frame>13 weeks</time_frame>
    <description>Change in SvO2 at rest, 25 watts and peak exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue</measure>
    <time_frame>13 weeks</time_frame>
    <description>Changes in levels of adipocyte differentiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue</measure>
    <time_frame>13 weeks</time_frame>
    <description>Changes in macrophage infiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue</measure>
    <time_frame>13 weeks</time_frame>
    <description>Changes in extracellular matrix fibrosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, coated tablets, once daily, for 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin tablet</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Sugar pill, visually identical to active comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of type 2 diabetes mellitus prior to baseline visit

          -  For patients on background therapy: stable dose of anti-diabetics within 30 days prior
             to baseline

          -  HbA1c of â¥7.0% and â¤10% at screening for patients on background therapy or HbA1c of
             â¥6.5 % and â¤ 9.0% at screening for drug-naÃ¯ve patients.

          -  BMI â¤ 45 kg/m at screening

          -  Age â¥18 years

          -  Patients must have high cardiovascular risk, defined as at least one of the following:

          -  Albuminuria ( albumin/creatinine ratio â¥ 30 mg/g or plasma NT-proBNP â¥ 70 pg/ml)

          -  Confirmed history of myocardial infarction (&gt;2 months prior to baseline)

          -  Or patient discharged from hospital with a documented diagnosis of unstable angina
             within 12 months prior to baseline

          -  Evidence of coronary artery disease by CAG in 1 or more major coronary arteries OR at
             least one of the following: a positive noninvasive stress test, or A positive stress
             echocardiography showing regional systolic wall motion abnormalities, or A positive
             scintigraphic test showing stress-induced ischemia,

          -  History of ischemic or haemorrhagic stroke (&gt;2 months prior to informed consent)

          -  Presence of peripheral artery disease (symptomatic or not ) documented by either:
             previous limb angioplasty, stenting or bypass surgery; or previous limb or foot
             amputation due to circulatory insufficiency; or angiographic evidence of significant
             (&gt; 50%) peripheral artery stenosis in at least one limb; or evidence from a
             non-invasive measurement of significant (&gt;50% or as reported as hemodynamically
             significant) peripheral artery stenosis in at least one limb; or ankle brachial index
             of &lt; 0.9 in

          -  Negative pregnancy test (fertile women). Fertile women must use safe contraceptives
             (spiral, hormonal contraceptives) for the duration of the study

          -  Able to understand the written patient information and to give informed consent

        Exclusion Criteria:

          -  Allergic to the study medication

          -  Treatment with SGLT-2 inhibitor within 3 months prior to baseline

          -  Impaired kidney function, eGFR â¤ 30 ml/min

          -  Severe liver insufficiency (Child-Pugh class C)

          -  ECG showing malign ventricular arrhythmia or prolonged QT-interval (&gt;500ms)

          -  Untreated clinical significant heart valve disease

          -  Planned cardiac surgery or angioplasty within 3 months.

          -  Myocardial infarction (MI) â¤ 30 days prior to baseline

          -  Percutaneous coronary intervention (PCI) â¤ 4 weeks prior to baseline

          -  History of coronary artery bypass graft (CABG) â¤ 8 weeks prior to enrollment

          -  Prior history of heart transplantation

          -  Unstable angina, known severe left main coronary artery stenosis, severe heart
             failure, uncontrolled arrhythmias, symptomatic hypotension or severe hypertension
             (systolic blood pressure &lt; 90 or &gt; 180 mmHg, respectively), sick sinus syndrome or &gt;
             1st degree atrioventricular block in the absence of a functioning pacemaker

          -  Requirement of emergent cardiac medical intervention or catheterization

          -  Treatment with theophylline, or theophylline containing medications

          -  History of known or suspected bronchoconstrictive or bronchospastic lung disease
             (e.g., asthma)

          -  Pregnancy or desire hereof or breastfeeding.

        Additional exclusion criteria for hemodynamics substudy

          -  LVEF â¤ 40 % evaluated at baseline echocardiography

          -  Inability to perform a VO2 max test

          -  Hypertrophic cardiomyopathy

          -  Left ventricular assist device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline M Kistorp, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev og Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel JÃ¼rgens, MD</last_name>
    <phone>+45 38682139</phone>
    <email>mikkel.juergens.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev og Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkel JÃ¼rgens, MD</last_name>
      <phone>+45 38 68 21 39</phone>
      <email>mikkel.juergens.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Caroline M Kistorp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikkel JÃ¼rgens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015 Mar;12(2):78-89. doi: 10.1177/1479164114561992. Epub 2015 Jan 23. Review.</citation>
    <PMID>25616707</PMID>
  </reference>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014 Oct 26;13:148. doi: 10.1186/s12933-014-0148-1.</citation>
    <PMID>25344694</PMID>
  </reference>
  <reference>
    <citation>deKemp RA, Yoshinaga K, Beanlands RS. Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow? J Nucl Cardiol. 2007 May-Jun;14(3):380-97. Review.</citation>
    <PMID>17556173</PMID>
  </reference>
  <reference>
    <citation>Naya M, Murthy VL, Foster CR, Gaber M, Klein J, Hainer J, Dorbala S, Blankstein R, Di Carli MF. Prognostic interplay of coronary artery calcification and underlying vascular dysfunction in patients with suspected coronary artery disease. J Am Coll Cardiol. 2013 May 21;61(20):2098-106. doi: 10.1016/j.jacc.2013.02.029. Epub 2013 Mar 21.</citation>
    <PMID>23524053</PMID>
  </reference>
  <reference>
    <citation>Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, Chow BJ, Min JK, Pencina MJ, Berman DS, Shaw LJ. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol. 2013 Jan 15;61(2):176-84. doi: 10.1016/j.jacc.2012.09.043. Epub 2012 Dec 5.</citation>
    <PMID>23219297</PMID>
  </reference>
  <reference>
    <citation>Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016 Jul;59(7):1333-1339. doi: 10.1007/s00125-016-3956-x. Epub 2016 Apr 25. Review. Erratum in: Diabetologia. 2016 Jul;59(7):1573-4.</citation>
    <PMID>27112340</PMID>
  </reference>
  <reference>
    <citation>HasenfuÃ G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG, Leon M, Kaye DM; REDUCE LAP-HF study investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016 Mar 26;387(10025):1298-304. doi: 10.1016/S0140-6736(16)00704-2.</citation>
    <PMID>27025436</PMID>
  </reference>
  <reference>
    <citation>ErsbÃ¸ll M, Valeur N, Mogensen UM, Andersen M, Greibe R, MÃ¸ller JE, Hassager C, SÃ¸gaard P, KÃ¸ber L. Global left ventricular longitudinal strain is closely associated with increased neurohormonal activation after acute myocardial infarction in patients with both reduced and preserved ejection fraction: a two-dimensional speckle tracking study. Eur J Heart Fail. 2012 Oct;14(10):1121-9. Epub 2012 Jun 28.</citation>
    <PMID>22753861</PMID>
  </reference>
  <reference>
    <citation>Jhund PS, Anand IS, Komajda M, Claggett BL, McKelvie RS, Zile MR, Carson PE, McMurray JJ. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015 Aug;17(8):809-17. doi: 10.1002/ejhf.274. Epub 2015 Apr 29.</citation>
    <PMID>25921853</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004 Nov;18(14):1692-700.</citation>
    <PMID>15522914</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 Apr 1;124(4):1868.</citation>
    <PMID>24463454</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016 May;65(5):1190-5. doi: 10.2337/db15-1356. Epub 2016 Feb 9.</citation>
    <PMID>26861783</PMID>
  </reference>
  <reference>
    <citation>Mudaliar S, Alloju S, Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.</citation>
    <PMID>27289124</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A &quot;Thrifty Substrate&quot; Hypothesis. Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330.</citation>
    <PMID>27289126</PMID>
  </reference>
  <reference>
    <citation>Aubert CE, Michel PL, Gillery P, Jaisson S, Fonfrede M, Morel F, Hartemann A, Bourron O. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014 Nov;30(8):679-85. doi: 10.1002/dmrr.2529.</citation>
    <PMID>24449227</PMID>
  </reference>
  <reference>
    <citation>Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, Jaarsma T, Schalkwijk C, van der Horst IC, Hillege HL, Voors AA. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J. 2012 Nov;164(5):742-749.e3. doi: 10.1016/j.ahj.2012.07.027.</citation>
    <PMID>23137505</PMID>
  </reference>
  <reference>
    <citation>Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007 Dec;9(12):1146-55. Review.</citation>
    <PMID>18023248</PMID>
  </reference>
  <reference>
    <citation>Oelze M, KrÃ¶ller-SchÃ¶n S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, Mader M, ZinÃius E, Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, MÃ¼nzel T, Daiber A. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014 Nov 17;9(11):e112394. doi: 10.1371/journal.pone.0112394. eCollection 2014.</citation>
    <PMID>25402275</PMID>
  </reference>
  <reference>
    <citation>JÃ¸rgensen RM, Levitan J, Halevi Z, Puzanov N, AbildstrÃ¸m SZ, Messier MD, Huikuri HV, Haarbo J, Thomsen PE, Jons C; CARISMA investigators. Heart rate variability density analysis (Dyx) for identification of appropriate implantable cardioverter defibrillator recipients among elderly patients with acute myocardial infarction and left ventricular systolic dysfunction. Europace. 2015 Dec;17(12):1848-54. doi: 10.1093/europace/euu394. Epub 2015 Mar 8.</citation>
    <PMID>25755288</PMID>
  </reference>
  <reference>
    <citation>Ruwald AC, Bloch Thomsen PE, Gang U, JÃ¸rgensen RM, Huikuri HV, Jons C. New-onset atrial fibrillation predicts malignant arrhythmias in post-myocardial infarction patients--a Cardiac Arrhythmias and RIsk Stratification after acute Myocardial infarction (CARISMA) substudy. Am Heart J. 2013 Nov;166(5):855-63.e3. doi: 10.1016/j.ahj.2013.08.017. Epub 2013 Sep 26.</citation>
    <PMID>24176441</PMID>
  </reference>
  <reference>
    <citation>RidderstrÃ¥le M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Erratum in: Lancet Diabetes Endocrinol. 2015 Sept;3(9):e7.</citation>
    <PMID>24948511</PMID>
  </reference>
  <reference>
    <citation>von Scholten BJ, Hasbak P, Christensen TE, Ghotbi AA, Kjaer A, Rossing P, Hansen TW. Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia. 2016 Feb;59(2):371-8. doi: 10.1007/s00125-015-3799-x. Epub 2015 Nov 2.</citation>
    <PMID>26526662</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Caroline M Kistorp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Any sharing of data must be approved by the regional ethics committee, and at the time of protocol writing there was no justification for data sharing outside of the current project</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

